Drug
Metreleptin clinical trials
- studies test it
- 23
- open now
- 2
- in phase 3
- 4
- first study started
- 2001
Keep track of what changes. Save the metreleptin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
23 studies that test it; most in 2001 (3)
| Year | Studies |
|---|---|
| 2001 | 3 |
| 2002 | 1 |
| 2003 | 2 |
| 2006 | 2 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 15
- Phase 3
- 4
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 14
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) · Beth Israel Deaconess Medical Center (4) · AstraZeneca (4) · University of Michigan (3) · Chiesi Farmaceutici S.p.A. (2) · Amryt Pharma (2) · Aegerion Pharmaceuticals, Inc. (1) · Elif Oral (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses metreleptin is read from its arms, and is right about nine times in ten.
Testing it · 23
- Open-label Extension Study to Evaluate Metreleptin in Patients With Partial LipodystrophyRecruitingPhase 3Chiesi Farmaceutici S.p.A.NCT06679270Written as Metreleptin
- Open-label Study to Evaluate Metreleptin in Patients With Partial LipodystrophyRecruitingPhase 4Amryt PharmaNCT06484868Written as Metreleptin
- Compassionate Use of Metreleptin in Previously Treated People With Generalized LipodystrophyActive, not recruitingPhase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT02262832Written as Metreleptin
- Compassionate Use of Metreleptin in Previously Treated People With Partial LipodystrophyActive, not recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT02262806Written as Metreleptin
- Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised LipodystrophyTerminatedPhase 3Amryt PharmaNCT06502990Written as Metreleptin
- Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLActive, not recruitingPhase 3Chiesi Farmaceutici S.p.A.NCT05164341Written as metreleptin
- Immunogenicity of Metreleptin in Patients With Generalized LipodystrophyCompletedPhase 4Aegerion Pharmaceuticals, Inc.NCT04026178Written as Metreleptin
- Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)Active, not recruitingPhase 2University of MichiganNCT05351164Written as Metreleptin
- Effect of Metreleptin Therapy in the Treatment of Severe Insulin ResistanceActive, not recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00085982Written as Metreleptin
- CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial LipodystrophyCompletedPhase 2University of MichiganNCT02654977Written as Metreleptin
- Short-term Effects of Leptin in People With LipodystrophyCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT01778556Written as Metreleptin
- Pharmacokinetics of Leptin Administration During FastingCompletedPhase 1Beth Israel Deaconess Medical CenterNCT00140205Written as r-metHuLeptin
- Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Elif OralNCT00596934Written as metreleptin
- Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With LipodystrophyCompletedPhase 2University of MichiganNCT01679197Written as Metreleptin
- Role of Leptin in the Neuroendocrine and Immune Response to FastingCompletedPhase 1/2Beth Israel Deaconess Medical CenterNCT00140231Written as r-metHuLeptin
- Study of Leptin for the Treatment of Hypothalamic AmenorrheaCompletedPhase 2Beth Israel Deaconess Medical CenterNCT00130117Written as r-metHuLeptin
- Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic SyndromeCompletedPhase 2Beth Israel Deaconess Medical CenterNCT00140244Written as r-metHuLeptin
- Leptin to Treat LipodystrophyCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00025883Written as Metreleptin
- Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy SyndromeCompletedNot applicableBaylor College of MedicineNCT01511016Written as Human recombinant leptin ("metreleptin")
- Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinCompletedPhase 2AstraZenecaNCT00819234Written as Pramlintide and Metreleptin
Codes
What other systems call metreleptin · ClinicalTrials.gg INT004283
- MeSH (NLM) C415771metreleptinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) TL60C27RLHMETRELEPTINConfirmed FDA, NLM, Wikidata
- RxNorm 1491625Confirmed FDA, Wikidata
- Wikidata Q17143468metreleptinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170171MetreleptinOne source FDA
- DrugBank DB09046One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C415771 | metreleptin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | TL60C27RLH | METRELEPTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1491625 | — | Confirmed FDA, Wikidata |
| Wikidata | Q17143468 | metreleptin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170171 | Metreleptin | One source FDA |
| DrugBank | DB09046 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.